MESO - メソブラスト (Mesoblast Limited) メソブラスト

 MESOのチャート


 MESOの企業情報

symbol MESO
会社名 Mesoblast Ltd (メソブラスト)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 メソブラスト(Mesoblast Limited)は骨髄や脂肪組織に由来製品の間葉系前駆細胞(MPC)技術プラットフォーム、歯髄幹細胞(DPSCs)、及び拡大造血幹細胞(HSC)を含むそのコア技術を活用した臨床開発会社である。同社の心臓血管と神経製品パイプラインはTeva Pharmaceutical Industries Ltd (Teva)との提携で開発された。同社の子会社にはMesoblast Inc.、Mesoblast International SA、Mesoblast Australia Pty Ltd及びMesoblast UK Limitedを含む。   メソブラストはオ―ストラリアバイオ医薬品企業。臨床開発段階で、骨髄と脂肪組織から派生した歯髄幹細胞と造血幹細胞を含む、間葉系幹細胞テクノロジ―プラットフォ―ムを利用した再生医療に取り組む。炎症に対する静脈内での治療、脊柱の整形、心血管や神経系疾患、目の脈管疾患などの治療を焦点に研究・開発を行う。本社はメルボルン。   Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.
本社所在地 Level 38 55 Collins Street Melbourne Victoria 3000 AUS
代表者氏名 Silviu Itescu Silviu Itescu
代表者役職名 Chief Executive Officer Executive Director
電話番号 +61 3-9639-6036
設立年月日
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 115人
url www.mesoblast.com
nasdaq_url https://www.nasdaq.com/symbol/meso
adr_tso 6854577
EBITDA EBITDA(百万ドル) -72.20000
終値(lastsale) 7.3
時価総額(marketcap) 50038412.1
時価総額 時価総額(百万ドル) 700.86350
売上高 売上高(百万ドル) 17.34100
企業価値(EV) 企業価値(EV)(百万ドル) 722.64750
当期純利益 当期純利益(百万ドル) -35.29000
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Mesoblast limited (ADR) revenues increased from $2.4M to $17.3M. Net loss decreased 54% to $35.3M. Revenues reflect Milestone revenue increase from $500K to $13.3M Commercialization revenue increase from $1.4M to $3.6M. Lower net loss reflects Remeasurement of contingent consideratio decrease from $130K (expense) to $10.5M (income) Management and administration - Balanci decrease of 5% to $19.9M

 MESOのテクニカル分析


 MESOのニュース

   Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Precigen, Royal Caribbean, Mesoblast, and Loop Industries and Encourages Investors to Contact the Firm - Stocks News Feed  2020/11/04 23:00:00 Stocks News Feed
NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN; XON), Royal Caribbean Group (NYSE: RCL), Mesoblast Limited (NASDAQ: MESO), and Loop Industries, Inc. (NASDAQ:… Read More »Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Precigen, Royal Caribbean, Mesoblast, and Loop Industries and Encourages Investors to Contact the Firm
   Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mesoblast Limited (MESO) - Stocks News Feed  2020/11/04 17:00:00 Stocks News Feed
LOS ANGELES, Nov. 04, 2020 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 7, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO) securities between April 16, 2019… Read More »Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mesoblast Limited (MESO)
   The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mesoblast Limited (MESO)  2020/10/30 15:30:00 Benzinga
LOS ANGELES , Oct. 30, 2020 /PRNewswire/ -- The Law Offices of Frank R. Cruz reminds investors of the upcoming December 7, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO ) securities between April 16, 2019 and October 1, 2020 , inclusive (the "Class Period"). If you are a shareholder who suffered a loss, click here to participate. In early 2020, Mesoblast completed its rolling submission of its Biologics License Application ("BLA") with the FDA to secure marketing authorization to commercialize remestemcel-L for children with steroid refractory aGVHD. On August 11, 2020 , the FDA released briefing materials for its Oncologic Drugs Advisory Committee … Full story available on Benzinga.com
   Mesoblast pins hopes on COVID-19 treatment  2020/10/29 06:26:51 The Australian Financial Review
The cash-burning biotech will report critical trial results for potential stem cell treatments for back pain, heart failure, and COVID-19 before Christmas.
   Mesoblast awaits urgent FDA meeting as cash burn continues - Stockhead  2020/10/29 02:52:04 Stockhead
Mesoblast says it burned through $US28.2 million in the third quarter, leaving it with $US108.1 million cash on hand as it awaits some key catalysts.
   Mesoblast (ASX:MSB) receives ethics approval to treat Covid-19 patients  2020/09/02 01:41:00 Finance News Network
02 Sep 2020 - Mesoblast (ASX:MSB) today announced that it has received ethics approval to include Australian hospitals in the controlled trial of remestemcel-L Covid-19 patients with acute respiratory distress syndrome (ARDS).
   Mesoblast reports FY results (NASDAQ:MESO)  2020/08/27 06:06:05 Seeking Alpha
Mesoblast (NASDAQ:MESO): FY GAAP EPS of -$0.147. Revenue of $32.16M (+92.3% Y/Y) The company reported 32% increase in royalty revenue on Temcell HS. Inj. s
   Mesoblast : Preliminary Final Report including Appendix 4E | MarketScreener  2020/08/26 22:17:07 MarketScreener
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F … | August 26, 2020
   Mesoblast shoots for the stars  2020/08/23 14:00:00 The Australian Financial Review
The biotech is awaiting critical news flow in 2020 over treatments for COVID-19, back pain, heart failure, and an inflammatory condition in children.
   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Mesoblast Limited and Encourages Investors with Losses of $100,000 to Contact the Firm  2020/08/17 01:55:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $MESO #MESO--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Mesoblast Limited

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 メソブラスト MESO Mesoblast Limited)

 twitter  (公式ツイッターやCEOツイッターなど)